CXCR4 and malignant colon neoplasm: [179] showed that combination therapy with the CXCR4 antagonist peptide R and chemotherapeutic agents inhibits cell proliferation and reverses EMT in colon cancer cells, thereby highlighting the importance of CXCR4 inhibitors in the management of chemoresistant CRC tumors.